TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39616603
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of HepB-CpG vaccine (n=169)
Study: 39616603
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of HepB-alum vaccine (n=165)
Study: 39616603
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of HepB-CpG vaccine
Study: 39616603
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of HepB-CpG vaccine
Study: 39617017
Drug: CTX130 (volamcabtagene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX130 (volamcabtagene durzigedleucel) at dose level 3 and higher
Study: 39617030
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min)
Study: 39617030
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human prourokinase
Study: 39617030
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min)
Study: 39617145
Drug: Mirvetuximab soravtansine
Normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks until progressive disease, unacceptable toxicity, withdrawal of consent, or death
Study: 39617530
Drug: BI 905677
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905677 at 2.8 mg/kg every 3 weeks
Study: 39617530
Drug: BI 905677
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905677 at 3.6 mg/kg every 3 weeks
Study: 39617530
Drug: BI 905677
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905677 (various doses)
Study: 39617535
Drug: BI 905681
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905681 (1.0, 2.5, 5.0, 7.0, and 8.5 mg/kg)
Study: 39617673
Drug: Oxylanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxylanthanum carbonate 1000 mg three times/day
Study: 39617673
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) 1000 mg three times/day
Study: 39617826
Drug: Tinostamustine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine, 100 mg/m²
Study: 39617826
Drug: Tinostamustine, RP2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine, RP2D (recommended Phase II dose)
Study: 39618195
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to subtype (esomeprazole for epigastric pain syndrome; itopride for postprandial distress syndrome; itopride with possible switch to esomeprazole at week 4)
Study: 39618195
Drug: Empirical proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical proton pump inhibitor (esomeprazole only)
Study: 39618204
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered before extubation
Study: 39618256
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks on background intranasal corticosteroids
Study: 39618477
Drug: Exogenous oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous oral progesterone (200 mg twice daily)
Study: 39618866
Drug: Low lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lung compliance (≤23.8 mL/cmH2O)
Study: 39618866
Drug: Higher lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher lung compliance (above 23.8 mL/cmH2O)
Study: 39619495
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (eTAU) control group
Study: 39620046
Drug: Bimekizumab (BKZ)
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab (BKZ) 160 mg every 2 weeks (Q2W; Weeks 0-10) then 320 mg Q4W (Weeks 12-44)
Study: 39620046
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg Q2W (Weeks 0-4), then 200 mg Q2W (Weeks 6-10), 400 mg Q4W (Weeks 12-44)
Study: 39620153
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with standard pharmacological treatment (EG)
Study: 39620153
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment with placebo acupuncture (CG)
Study: 39620201
Drug: PNET HR+5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNET HR+5 regimen (intensive pediatric chemotherapy)
Study: 39621728
Drug: DMC laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMC laser diode (λ = 808 nm), 4J per point, 100mW of power, 1,016W/cm2, 8 sites in the vulvar region, four consecutive applications, weekly.
Study: 39621979
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (n = 15)
Study: 39622410
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) plus Ramucirumab (10 mg/kg every two weeks)
Study: 39622578
Drug: Optimisation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan
Study: 39622823
Drug: Adjunctive rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive rosuvastatin
Study: 39623365
Drug: Mesoglycan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (200 mg for the first 5 days, then 100 mg for the subsequent 35 days, twice daily)
Study: 39623426
Drug: ADSC spray
Normalized name: Asparagus adscendens root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADSC spray therapy
Study: 39623502
Drug: Extended-release buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release buprenorphine (XR-BUP) - single injection of a 28-day formulation within 72-hours of anticipated hospital discharge.
Study: 39623502
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - may consist of any MOUD other than XR-BUP.
Study: 39623502
Drug: Extended-release buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release buprenorphine (XR-BUP)
Study: 39623757
Drug: Advanced systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced systemic therapy (AST) including dupilumab and upadacitinib
Study: 39623757
Drug: Advanced systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced systemic therapy (AST)
Study: 39624459
Drug: Apomorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine treatment (30-day subcutaneous administration)
Study: 39624459
Drug: Apomorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine treatment
Study: 39624736
Drug: Topical OA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical OA 0.5%
Study: 39624736
Drug: Topical retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical retinol 0.5%
Study: 39624747
Drug: Microwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave treatment (Swift device)
Study: 39624833
Drug: HAIC sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC sequential TAE combined with tislelizumab and surufatinib
Study: 39624922
Drug: Higher HBcrAg
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HBcrAg levels at end of treatment (EOT)
Study: 39625044
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two consecutive markers
Study: 39625230
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg every 4 weeks (Q4W) with topical corticosteroids (TCS)
Study: 39625230
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg every 2 weeks (Q2W) with topical corticosteroids (TCS)
Study: 39625244
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg daily starting post-operative day 2 until 1 day after chest tube removal
Study: 39625478
Drug: Duvelisib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib (25 mg orally twice daily) with docetaxel (75 mg/m2 IV every 21-days)
Study: 39625569
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide
Study: 39625696
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous 15 mg/kg amikacin dose
Study: 39625696
Drug: Flat 1500-mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat 1500-mg dose
Study: 39625696
Drug: Flat 3500-mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat 3500-mg dose
Study: 39625696
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg dosing
Study: 39625722
Drug: Fostamatinib, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib, 150 mg orally twice daily for 14 days
Study: 39626074
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patches
Study: 39626074
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for sertraline
Study: 39626127
Drug: IV ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV ocrelizumab 600 mg every 24 weeks
Study: 39626160
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg orally once daily on a 28-day cycle
Study: 39626300
Drug: Inaticabtagene Autoleucel
Normalized name: Inaticabtagene Autoleucel
DrugBank: Inaticabtagene Autoleucel (DB18356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inaticabtagene Autoleucel (Inati-cel) infusion
Study: 39626332
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT with CF)
Study: 39626345
Drug: Adipocyte size
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipocyte size measurement in various fat depots (subcutaneous, visceral, retroperitoneal, mammary)
Study: 39626378
Drug: Aβ-hTreg (VT301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aβ-hTreg (VT301) low dose
Study: 39626378
Drug: Aβ-hTreg (VT301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aβ-hTreg (VT301) high dose
Study: 39627123
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) interventions selected by an algorithm
Study: 39627133
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor (ICI) rechallenge
Study: 39627217
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg daily for 12 months
Study: 39627624
Drug: Submucosal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submucosal dexamethasone (8 mg, 2 mL)
Study: 39627701
Drug: RSM01 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSM01 (300 mg IV, 300 mg IM, 1000 mg IV, 3000 mg IV, 600 mg IM)
Study: 39627786
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment for 2 weeks
Study: 39627789
Drug: Adapted STAIR-NT
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted STAIR-NT intervention (massed treatment model with four 60-min sessions of skill building and two weeks of four 60-min sessions of narrative therapy)
Study: 39627831
Drug: Active pulse
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulse electromagnetic field therapy and standard exercise training
Study: 39627831
Drug: Sham pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulse electromagnetic field therapy and standard exercise training
Study: 39628466
Drug: Polyphenol-rich supplement
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich supplement (specific dosage and duration not mentioned)
Study: 39628618
Drug: Miglustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat (100 mg twice daily to 200 mg three times daily)
Study: 39629185
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) and positive psychology therapy (PPT)
Study: 39629675
Drug: Modified cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cycles approach administered by an SLT and a student clinician
Study: 39629836
Drug: CAM2038 subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections
Study: 39629836
Drug: Daily sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sublingual (SL) BPN/naloxone (BPN/NX) tablets
Study: 39630028
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) treatment
Study: 39630028
Drug: Non-OCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-OCA treatment (control)
Study: 39630057
Drug: Modakafusp alfa
Normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modakafusp alfa at 1.5 mg/kg every 4 weeks (Q4W)
Study: 39630057
Drug: Modakafusp alfa
Normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modakafusp alfa therapy
Study: 39630067
Drug: Beta-lactam antibiotics
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotics (11 different types)
Study: 39631702
Drug: D-Cycloserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine (100 mg) with daily intermittent theta-burst stimulation (iTBS)
Study: 39631702
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with daily intermittent theta-burst stimulation (iTBS)
Study: 39632107
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with cadonilimab (SOX regimen with cadonilimab)
Study: 39633105
Drug: Automated text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated text messaging program prompting weekly BP checks for 6 months.
Study: 39633112
Drug: Melatonin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 60 mg/day starting 5 days before surgery
Study: 39633112
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment starting 5 days before surgery
Study: 39633218
Drug: Plasma 10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma 10-15 ml/kg
Study: 39633261
Drug: Educational booklet
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational booklet on falls prevention and behavioral treatment for urinary incontinence (control group)
Study: 39633319
Drug: Therapist competence
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist competence (assessed using the Cognitive Therapy Scale-Revised)
Study: 39633321
Drug: High-fiber dietary
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber dietary intervention (HFDI) with a target fiber of 50 g/day from whole foods
Study: 39633321
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control diet with a target fiber of 20 g/day
Study: 39633367
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education materials (Control group).
Study: 39633405
Drug: manual-based videoconferencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: manual-based videoconferencing cognitive behavioral therapy (vCBT)
Study: 39633570
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 2g administered within 45 minutes of symptom onset
Study: 39633573
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose Heparin
Study: 39635465
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg once daily for 12 weeks
Study: 39636384
Drug: Super-resolution ultrasound
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-resolution ultrasound (SR-US) imaging after bolus injection of microbubbles at clinical concentration
Study: 39636496
Drug: Initiating medications
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initiating medications for opioid use disorder (MOUD) prior to release
Study: 39636496
Drug: Linkage to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linkage to ongoing MOUD treatment in the community
Study: 39636496
Drug: Peer support-facilitated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support-facilitated treatment retention efforts
Study: 39636502
Drug: Remote, tablet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote, tablet-based patient video education intervention focused on cancer care coordination
Study: 39636623
Drug: Intratumoral delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral delivery of conventional type 1 dendritic cells (cDC1), 6 times weekly, followed by paclitaxel (80 mg/m2, intravenously, 12 times weekly), trastuzumab (8 mg/kg loading dose, then 6 mg/kg), and pertuzumab (840 mg loading dose, then 420 mg) every 3 weeks for 6 cycles starting from day 1 of cDC1 injections.
Study: 39636638
Drug: Psilocybin, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin, 25 mg
Study: 39636638
Drug: Niacin, 100
Normalized name: Niacin, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin, 100 mg
Study: 39636679
Drug: Oral screen
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral screen training for 12 weeks
Study: 39636679
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral screen training)
Study: 39637307
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus hypomethylating agents
Study: 39637726
Drug: Brivaracetam (≤5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (≤5 mg/kg/day, ≤200 mg/day)
Study: 39637944
Drug: Tremelimumab +
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab + Durvalumab (T300/D) as neoadjuvant treatment
Study: 39637944
Drug: Tremelimumab +
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab + Durvalumab (T300/D) as definitive treatment
Study: 39638148
Drug: Oral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-citrulline supplementation
Study: 39638275
Drug: Catheter-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed therapy (CDT) plus anticoagulation
Study: 39638585
Drug: ACTION (Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTION (Acceptance and Commitment Therapy Intervention when Opioids are Necessary)
Study: 39638596
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment followed by application of autologous bioartificial palate mucosa
Study: 39638596
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment (control group)
Study: 39638782
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab with bevacizumab and oral cyclophosphamide
Study: 39639282
Drug: Creative writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative writing intervention combined with standard treatment
Study: 39640075
Drug: Uchasingihwan (UCSGH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uchasingihwan (UCSGH) 2.5 g granule three times a day for six weeks
Study: 39640075
Drug: loxoprofen 60
Normalized name: loxoprofen 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loxoprofen 60 mg tablet three times a day for six weeks
Study: 39641169
Drug: Daily avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily avocado consumption
Study: 39641725
Drug: FFR-guided PCI
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided PCI with current generation drug-eluting stents (DES)
Study: 39641856
Drug: Anidulafungin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (200 mg on day 1, then 100 mg daily)
Study: 39641926
Drug: DPYD/UGT1A1 pharmacogenetic-informed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD/UGT1A1 pharmacogenetic-informed therapy
Study: 39641985
Drug: Self-help program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help program intervention delivered via an automated conversational agent on WhatsApp